Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

After dropping efforts to obtain approval of Nuvigil (armodafinil) for treatment of jet lag disorder, Cephalon is left with one possible new indication for the wakefulness drug: depression associated with bipolar disorder.
Advertisement

Related Content

Teva’s Nuvigil Label-Expansion Effort Shows No Signs Of Fatigue Even After Bipolar Depression Failure
Teva’s Nuvigil Label-Expansion Effort Shows No Signs Of Fatigue Even After Bipolar Depression Failure
Still Seeking New Growth Areas, Cephalon Reassures Investors It Can Continue To Build Nuvigil And Treanda
Cephalon Looks For Growth as Nuvigil Fails Schizophrenia Trial
Cephalon's Nuvigil Jet Lag Indication Grounded By Complete Response Letter
Cephalon's Nuvigil Jet Lag Indication Grounded By Complete Response Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS004635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel